We performed immunostaining for S100A2 in the skin and evaluated the difference in its distribution in the epidermis between mild and severe forms of drug eruptions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. This evidence concerns the gene S100A2 and toxic epidermal necrolysis.